Member Info for spinnaker

I have just sent an email to three addresses at Clinigen as below and will let you know the response.

Dear Julie

Thank you for your email below. I note that we have had a massive resurgence of Covid in the UK and it is obviously causing huge disruption. Worse than that, the hospital beds are now very full with sick patients. Although you have many clients it could be that Synairgen is currently one of the most important.

Given that the SNG001 treatment has not yet been given full authorisation it seems the very important ball is now in Clinigen’s court to enable as widespread use and as many lives saved as possible.

I would be grateful if you could please answer the following questions for me.

1) What marketing and promotion in relation to the availability of SNG001 treatment under MAP have you carried out and what limitations are there within relevant Codes of Practice or professional guidelines? If none carried out, is this due to restrictions in your remit from Synairgen?

2) How many treatment courses have been applied for and how many responsible doctors does this involve and in which countries?

3) How many treatment courses have now been authorised and distributed under MAP and in which countries?

4) What are your targets or anticipation for treatment course distribution to patients within the next three months and to which countries?

5) Are you responsible for collating/monitoring progress in patients and outcomes so that data can be useful prior to P3 Trial readouts? If not who is?

I look forward to receiving your response as a shareholder in both Clinigen and Synairgen.

Many thanks

Kind regards and best wishes for Christmas.

From: Julie Gosper [mailto:Julie.Gosper@clinigengroup.com]

I'm in the same boat CW25. No idea where to start and for an accountant to plough through hundreds of trades is going to cost a fortune I'm sure. I have read that if your total gain is less than £12,500 or thereabouts and your the disposal value is less than 4 times that figure there is no need to enter anything in the tax return. I have asked H/L if they can provide the necessary figures for my fund and share account but they don't have this facility at present.

So if you add or sell any shares of the same company within 30 days of the last trade the disposal doesn't count for CGT. Very complicated rules. I would have thought there was some readily available software to sort it out and really do think this should be provided by H/L. Does any other platform do the number crunching, anyone know?

Spinnaker

Has anyone emailed Clinigen to see how the roll-out under MAP is going? I presume they are allowed to contact medics to apprise them of the availability criteria.

If no-one else has, I may email them.

Spinnaker

I think there is bound to be a worldwide market for SNG but we have no patent protection at present for anywhere other than US and Europe/UK as far as I understand. I don't know the company plans for rolling this out worldwide or the rules re patents but I would expect SNG would want to partner with large Pharma in India or China and make urgent patent application in order to protect IP in RoW.

Spinnaker

Turkishdreams

That is an uplifting story and fantastic that you will achieve your dreams after four horrible years. Congratulations.

Very best wishes for Christmas and a healthy 2021 and beyond to you and your husband.

Spinnaker

Docdaneeka

I just spoke to a doctor friend, just retired this year. She said she didn't know until today that the vaccine wasn't proven to prevent transmission. That is a different point but reinforces yours that the information campaign through all formats is vital.

Spinnaker

It's all very well pontificating but nobody knows why the share price has risen or if there are discussions on sale.
For what it is worth my thoughts are.

1) I really expected a tie in with a large US pharma following P2 results in July leading to swift roll-out of P3 and probable EUA by November and/or full US licence by now.

2) There are only two reasons that I can think of that this didn't happen, either
a) RM and the board wanted too much of the pie and all offers were refused, or
b) None of the large Pharmas made an offer since they thought it was too high risk for the cost.

3) If the above is true, what has changed? There are no further research outcomes or approvals to date, only the Lancet Peer review which hasn't changed the basics.

4) Half of the money raised at 175p is going towards international P3 trials which haven't started yet as far as we know and there is no indication of read-out date. Likely to be at least 3 months and possibly more.

5) SNG are now funded to complete P3 trials and the Board will be anticipating very good results. I therefore think it is unlikely that RM would have reduced his value expectation since July and therefore acceptance of an offer near 175p is unthinkable.

Spinnaker

Sharestobuy
The clue is in the heading. The FDA is in the US. You obviously didn't bother to click on the link.
Very interesting though.

Legalwolf

Can I ask? Are you thinking that N.D.A. means Non Disclosure Agreement or New Drug Application?
When I first read your post, the former was my immediate assumption which is more in my field of knowledge but I recently read another poster that stated it meant the latter. Your post appears to imply the former.

Many thanks

Feeling imbecilic, Spinnaker

Thanks for your responses. I see two common Directors. I was fairly gobsmacked to see that TILS has had 36 Officers over the past 25 years and all but 5 have resigned!

I should have done a bit more DD here.

Spinnaker

I do think that the BoD here has been pretty damn subterranean in its communication with shareholders since the massive pumping before the fund raising both placing and ATM. Admittedly this was compounded by silly US confusion with TESLA. The confusion on time difference between UK and US split dates was more than unhelpful. However the current shenanigans with the de-merger of Accustem and listing for TILS on the main market is really screwing confidence even more.

I don't have a clue whether there is a Board of Directors for Accustem, whether there are any employees or premises. All I understand is the company will have £1m plus some IP relating to breast cancer products, Therefore is it really just a shell that can't go anywhere without being purchased or requiring significant fundraising? I am sure you are correct John Law. There was a load of hype on this board suggesting the de-merger would result in a massive windfall to TILS holders. I never really accepted that view and there was certainly no rush into the shares before de-merger. I really can't see significant value in Accustem now unless negotiations are already very far advanced for a sale of the new company. The date for trading of new shares has not yet been announced and will not now be until January or later if it actually occurs. I expect talk of £1 per share is totally pie in the sky unless there is a large buyer.

I am well underwater in TILS and wish I had the confidence of Shiraz to invest more funds to reduce my average even on a medium/long term view. I agree with other posters that the BoD have not taken advice of the right calibre judging by what has happened over the last six months. Certainly the short term does not show any likelihood of earnings potential even post the Phase 1 trial in Brazil for Covid treatment.

Now a rather concerned investor but one who will have to continue holding now I see a fairly limited downside at this SP.

Spinnaker

Thanks Floater and Welsh Falcon. I understand and and think your points are well made. A symbiotic relationship between Newcrest and Greatland is good for both parties and lets hope the excellent relationship continues. It looks like the GB / EU relationship is coming under pressure under pressure unfortunately.

Spinnaker

Welsh Falcon

I was concerned whether Mining News were pricing in US or AUS $ but it seems to be AUS $.

At an average of A$2500 per oz AISC it would seem that Telfer is breaking even, not running at a huge loss since A $2,500 was the average spot price for gold during the period reported. At current rates it seems US$1800 p oz = AUS$2,400 so not huge losses keeping Telfer open.
Nevertheless this does not detract from Paddy's point that the average cost of extraction at Telfer seems to be increasing fast and therefore without Havieron or a significant PoG increase Telfer would probably have to close soon.

Surely this bodes well for GGP's negotiating strength and also the speed that Newcrest will want to progress to mining as others have stated. All very positive combined with possible inclusion in GDX next March

Spinnaker

Thanks for that info MF11.

Now I have confused myself.

What I suppose happens is if GGP SP moves in line with other miners then the number of shares required to be held by GDXJ will remain the same but since GGP has undoubtedly been outperforming the market the proportion of capital value of GGP required to be held would increase and I suppose you have a point. This would be automatically be reflected in the increased value of the GGP holding due to the SP increase. Therefore is there any significant share sale or purchase required?

Spinnaker

SG

I believe the GDXJ proportion will increase with increase in MC not the opposite.

I am delighted that GGP is the one share I have that is doing its best to offsett huge losses in some other holdings. Thanks very much for the excellent postings here from Paddy, Hydrogen etc. This has been the share that has caused me least concern since what has been found cannot be lost.

Spinnaker

The Daily Mail also mentions anticipated Peer Reviewed publication. That will take another four months if SNG's wait is any indication! Ha Ha!

Spinnaker

LiveLif

I entirely agree with your quote. The only problem is your initial statement is 'non sequitor'. Asymptomatic individuals are not generally tested nor contacts traced. You will note the word 'illness' is used implying symptoms.

Spinnaker

Yes Borsac

Thanks for that link. This is what Michael Mina and others have been saying for months. The fact is that our testing in the UK is usually done on symptomatic individuals possibly 24 to 48 hours after first symptoms. Symptoms first occur between two and five days after infection Results probably 24 to 48 hours after tests. This means that test results are only available between 4 days minimum and 9 days maximum after infection and, according to Mina, well after peak infectiousness which is almost always before symptoms occur and probably within 48 hours of initial infection. Obviously asymptomatic individuals which may be the majority are entirely missed by the tests because they won't have one unless part of a trial/mass community testing process.

The upshot of this is that our current testing regime will only have a very minor impact on preventing the spread of the disease whilst insisting people quarantine when for the most part they will be no longer infectious .

Spinnaker

Thanks for that Chris T and crippz.

I am at total fault here since I only red the first couple of pages of the 14 Oct RNS despite then applying for a ridiculously large number of placing shares. I see that is £30m accounted for then.

Spinnaker